Un nouvel outil pour détecter le cancer de la vessie.

A new tool to monitor bladder cancer is four times more effective than the conventional laboratory test in detection of the disease.

Un nouvel outil pour surveiller le cancer de la vessie est 4 fois plus performant que les tests conventionnels de laboratoire.

According to the January edition of the Journal of American Medical Association, researchers led by The University of Texas M.D. Anderson Cancer Center, at 23 clinical sites, enrolled 668 patients with a history of bladder cancer, to look at how NMP22 assay effects the detection of recurrences. It in now apparent that the NMP22 assay detected 49.5 percent of recurrences (51 out of 103) when urine cytology detection was only 12.2 percent (12 out of 98). When combined with cystoscopy NMP22 assay detected 99 percent of bladder cancers and an improvement of 8 percent when using cystoscopy alone.%uFFFD Bladder cancer is the 5th most common cancer in the United States, and the possibility of it recurring is as high as 50 percent. These improvements in detection will help prevent the advancement of the bladder cancer before it requires aggressive treatment

Ces améliorations dans la détection aideront à prévenir le cancer de la vessie avant qu'ils requierrent des traitements agressifs.